Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly -: A comparative review

被引:130
作者
Allain, H
Bentué-Ferrer, D
Polard, E
Akwa, Y
Patat, A
机构
[1] Univ Rennes 1, Fac Med, Lab Expt & Clin Pharmacol, F-35043 Rennes, France
[2] Univ Rennes 1, Fac Med, CMRR, F-35043 Rennes, France
[3] Hop Pontchaillou, Ctr Reg Pharmacovigilance, Rennes Med Sch, Rennes, France
[4] INSERM, U488, F-94275 Le Kremlin Bicetre, France
[5] Biotrial SA, Rennes, France
关键词
D O I
10.2165/00002512-200522090-00004
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The aim of this review is to establish the relationship between treatment with hypnotics and the risk of postural instability and as a consequence, falls and hip fractures, in the elderly. A review of the literature was performed through a search of the MEDLINE, Ingenta and PASCAL databases from 1975 to 2005. We considered as hypnotics only those drugs approved for treating insomnia, i.e. some benzodiazepines and the more recently launched 'Z'-compounds, i.e. zopiclone, zolpidem and zaleplon. Large-scale surveys consistently report increases in the frequency of falls and hip fractures when hypnotics are used in the elderly (2-fold risk). Benzodiazepines are the major class of hypnotics involved in this context; falls and fractures in patients taking Z-compounds are less frequently reported, and in this respect, zolpidem is considered as at risk in only one study. It is important to note, however, that drug adverse effect relationships are difficult to establish with this type of epidemiological data-mining. On the other hand, data obtained in laboratory settings, where confounding factors can be eliminated, prove that benzodiazepines are the most deleterious hypnotics at least in terms of their effects on body sway. Z-compounds are considered safer, probably because of their pharmacokinetic properties as well as their selective pharmacological activities at benzodiazepine-1 (BZI) receptors. The effects of hypnotics on balance, gait and equilibrium are the consequence of differential negative impacts on vigilance and cognitive functions, and are highly dose- and time-dependent. Z-compounds have short half-lives and have less cognitive and residual effects than older medications. Some practical rules need to be followed when prescribing hypnotics in order to prevent falls and hip fractures as much as possible in elderly insomniacs, whether institutionalised or not. These are: (i) establish a clear diagnosis of the sleep disorder; (ii) take into account chronic conditions leading to balance and gait difficulties (motor and cognitive status); (iii) search for concomitant prescription of psychotropics and sedatives; (iv) use half the recommended adult dosage; and (v) declare any adverse effect to pharmacovigilance centres. Comparative pharmacovigilance studies focused on the impact of hypnotics on postural stability are very much needed.
引用
收藏
页码:749 / 765
页数:17
相关论文
共 102 条
[1]   General safety profile of zolpidem: Safety in elderly, overdose and rebound effects [J].
Allain, H ;
Monti, J .
EUROPEAN PSYCHIATRY, 1997, 12 :S21-S29
[2]   Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects.: A randomized, cross-over, double-blind study versus placebo [J].
Allain, H ;
Bentué-Ferrer, D ;
Tarral, A ;
Gandon, JM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (03) :179-188
[3]   Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg [J].
Allain, H ;
Bentué-Ferrer, D ;
Le Breton, S ;
Polard, E ;
Gandon, JM .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (05) :369-374
[4]   POSTMARKETING SURVEILLANCE OF ZOPICLONE IN INSOMNIA - ANALYSIS OF 20,513 CASES [J].
ALLAIN, H ;
DELAHAYE, C ;
LECOZ, F ;
BLIN, P ;
DECOMBE, R ;
MARTINET, JP .
SLEEP, 1991, 14 (05) :408-413
[5]   Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics [J].
Allain, H ;
Patat, A ;
Lieury, A ;
LeCoz, F ;
Janus, C ;
Menard, G ;
Gandon, JM .
EUROPEAN PSYCHIATRY, 1995, 10 :S129-S135
[6]  
Ancoli-Israel S, 2000, SLEEP, V23, pS23
[7]   Sleep changes and disorders in the elderly patient. [J].
Avidan A.Y. .
Current Neurology and Neuroscience Reports, 2002, 2 (2) :178-185
[8]   Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in michigan nursing homes [J].
Avidan, AY ;
Fries, BE ;
James, ML ;
Szafara, KL ;
Wright, GT ;
Chervin, RD .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (06) :955-962
[9]   CLINICAL PHARMACOKINETICS OF BENZODIAZIPINES [J].
BAILEY, L ;
WARD, M ;
MUSA, MN .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) :804-811
[10]   Benefit-risk assessment of zaleplon in the treatment of insomnia [J].
Barbera, J ;
Shaprio, C .
DRUG SAFETY, 2005, 28 (04) :301-318